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effect on within-visit variability in diastolic BP ( p = 0.38) or 
heart rate ( p = 0.07). Neither morning home BP variability 
(systolic BPV,  p = 0.81; diastolic BPV,  p = 0.46) nor day-to-day 
variability in home BP measurements (systolic BPV,  p = 0.61; 
diastolic BPV,  p = 0.58) differed significantly between the 
groups.  Conclusion: CPAP withdrawal results in a minor in-
crease in within-visit variability in office systolic BP, but it has 
no effect on home BPV or day-to-day BPV. Although the 
treatment effect may be blunted by antihypertensives, it is 
unlikely that OSA contributes to cardiovascular risk via ele-
vated daytime BPV.  © 2017 S. Karger AG, Basel 
 Introduction 
 Obstructive sleep apnoea (OSA) has been identified as 
a common factor associated with hypertension and car-
diovascular disease (CVD), although potential causal 
mechanisms have not been fully elucidated  [1] . The prev-
alence of OSA is likely to further increase as a result of 
increasing obesity  [2] . Observational and population-
based epidemiological studies have shown that untreated 
moderate-to-severe OSA is associated with hypertension 
and adverse cardiovascular outcome  [3–7] . However, 
randomised controlled trials on the effects of continuous 
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 Abstract 
 Background: Increased daytime blood pressure variability 
(BPV) is associated with cardiovascular risk. Preliminary data 
suggest that obstructive sleep apnoea (OSA) might contrib-
ute to increased daytime BPV.  Objective: The aim of this 
study was to evaluate the effect of continuous positive air-
way pressure (CPAP) therapy withdrawal on daytime BPV. 
 Methods: A total of 183 patients previously diagnosed with 
OSA and treated with CPAP were randomised to either con-
tinue or withdraw from CPAP within 4 trials. Office morning 
BP was measured in triplicate at baseline and at follow-up 
(day 14). In addition, the participants performed BP mea-
surements at home on a daily basis (days 1–13). The main 
outcome of interest was the treatment effect on within-visit 
BPV expressed as the standard deviation (SD) of the triplicate 
measurements. Additional outcomes included morning 
home BPV and day-to-day home BPV.  Results: Within-visit 
variability in systolic BP significantly increased in response to 
recurrence of OSA in the CPAP withdrawal group (difference 
between groups in SD of systolic BPV, +1.14 mm Hg, 95% CI 
+0.20/+2.09,  p = 0.02). There was no statistically significant 
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positive airway pressure (CPAP) therapy have so far only 
established a causal association between OSA and diurnal 
hypertension  [8] .
 Hypertension is an established risk factor for CVD  [9] . 
In recent years, not only sustained blood pressure (BP) 
elevation itself but also BP variability (BPV) have been 
recognised as important predictors of CVD  [10–12] ; 
there seems to be a connection between high BPV and 
increased cardiovascular morbidity and mortality, even 
in patients with well-controlled BP  [11–14] . These find-
ings have been linked to alteration of vascular reactivity 
due to, amongst other factors, increased arterial stiffness 
and endothelial dysfunction  [15–17] . Similarly, impaired 
endothelial function has been observed in OSA patients 
 [18–20] , possibly linking the underlying pathophysiology 
of OSA and elevated BPV. Furthermore, the consequenc-
es of OSA involve numerous mechanisms such as auto-
nomic dysregulation and increased sympathetic activity, 
thus linking OSA to elevated BP levels and potentially to 
increased BPV  [21, 22] . One might, therefore, hypothe-
sise that not only elevated BP levels but also increased 
BPV may be caused by OSA and contribute to the associ-
ated adverse cardiovascular outcomes.
 An association between the severity of OSA and BPV 
has previously been described in physiologic and obser-
vational studies  [23, 24] . While it could be shown that 
CPAP therapy effectively abolishes OSA  [25] , improves 
endothelial function  [26, 27] , and reduces BP  [8] , there 
are controversial data on the effect of CPAP therapy on 
daytime BPV  [28, 29] . Although there have been studies 
on the association of OSA with BPV, evidence from ran-
domised controlled interventional trials is missing.
 Short-term CPAP therapy withdrawal has been shown 
to result in the recurrence of OSA and its consequences 
such as increased BP, sympathetic activity, and impaired 
endothelial function  [20, 30] . Therefore, we considered 
this study design suitable to evaluate the effects of CPAP 
withdrawal on BPV. We hypothesised that the recurrence 
of OSA in response to therapy withdrawal would result in 
an increase in within-visit BPV as well as in short-term 
morning home BPV and intermediate-term day-to-day 
BPV.
 Subjects and Methods 
 Trial Design and Intervention 
 Four randomised controlled trials, which allocated CPAP-
treated patients to either continue or withdraw from CPAP for 2 
weeks, were conducted in Zurich and Oxford between 2010 and 
2015  [20, 30–32] . Patients registered in the sleep database of the 
Sleep Disorders Centre and Pulmonary Division of the University 
Hospital Zurich, Zurich, Switzerland, and of the Centre for Respi-
ratory Medicine, Oxford, UK, were recruited. Baseline examina-
tions on therapeutic CPAP therapy were performed in both study 
arms. The morning after the baseline sleep studies, the patients 
were randomly assigned to either continue therapeutic CPAP or 
withdraw from CPAP (subtherapeutic sham CPAP or non-thera-
peutic nasal device) and returned 2 weeks later for the follow-up 
sleep study on the assigned treatment. Morning BP was measured 
daily in triplicate during the study period. The studies were ap-
proved by the research ethics committees in Zurich (EK-1600, 
KEK-ZH-2012-051) and Oxford (11/NW/0370). Written in-
formed consent was obtained from all participants. The trials
were registered prior to commencement (ClinicalTrials.gov 
NCT01332175, NCT01797653, and NCT02050425; controlled-
trials.com: ISRCTN 93153804).
 Participants 
 Subjects with known OSA were recruited from the Sleep Dis-
orders Centre and Pulmonary Division of the University Hospital 
Zurich and from the Centre for Respiratory Medicine in Oxford. 
Patients aged 20–75 years with an oxygen desaturation index 
(ODI) of  ≥ 10/h  [20, 30] or 20/h  [31, 32] in their in-laboratory sleep 
study at the time of diagnosis were eligible if they had been treated 
with CPAP for at least 1 year (compliance of  ≥ 4 h/night) and cur-
rently had an ODI >10/h  [20, 30] or >20/h  [31, 32] in a nocturnal 
pulse oximetry assessment on the last night of a 4-night period off 
CPAP treatment. Exclusion criteria were ventilatory failure, 
Cheyne-Stokes respiration, unstable or untreated vascular disease, 
inadequately controlled arterial hypo- or hypertension, profes-
sional driving, and a previous traffic accident associated with 
sleepiness.
 Outcomes 
 The main outcome of interest was the treatment effect on with-
in-visit BPV (standard deviation [SD] of 3 repeated office BP mea-
surements [day 0 and day 14]). Other outcomes of interest were 
short-term morning home BPV (mean daily SD of 3 repeated 
home BP measurements over 2 weeks: [SD triplet1 + SD triplet2 + … + 
SD triplet13 ]/13) and intermediate-term day-to-day BPV (SD of dai-
ly mean home BP over 2 weeks: SD of [BP 1 + BP 2 + … + BP 13 ]), as 
well as heart rate (HR) variability over the whole study period and 
effects on sleep apnoea severity (ODI).
 After the baseline and follow-up sleep studies, morning office 
BP and HR were measured in triplicate (1-min intervals) with a 
validated standard digital automatic monitor (Omron Healthcare 
Co., Kyoto, Japan). In addition, the patients measured their home 
morning BP and HR in triplicate with the same device each day 
during the study period. The measurements were performed ac-
cording to a standardised protocol: in a sitting position after a pe-
riod of rest of  ≥ 5 min, immediately after getting up, before break-
fast, and before intake of antihypertensive drugs, with 1-min inter-
vals between the 3 measurements. The sleep studies and therapy 
devices (CPAP, subtherapeutic CPAP, and ineffective nasal devic-
es) have previously been described  [20, 30–32] .
 Randomisation and Blinding 
 The methods of randomisation and blinding have been report-
ed previously  [20, 30–32] . The patients and investigators were 
blinded to treatment allocation.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
13
6 
- 1
/2
3/
20
18
 4
:0
8:
18
 P
M
 Blood Pressure Variability in OSA Respiration 2017;93:311–318
DOI: 10.1159/000465528
313
 Statistical Methods 
 A per-protocol analysis was performed. The Kolmogorov-
Smirnov test was used to test for normality of data distribution. For 
the main outcome of interest, between-group differences in change 
of within-visit BPV from baseline to follow-up were adjusted for 
baseline differences using linear regression models. For the addi-
tional outcomes, group differences between the patients ran-
domised to continue and those randomised to withdraw from 
therapeutic CPAP were analysed with independent  t tests for nor-
mally distributed and with Mann-Whitney U tests for non-nor-
mally distributed data. Analyses were conducted at a 2-sided sig-
nificance level of <0.05. Statistica (version 12 for Windows; Stat-
Soft Inc., Tulsa, OK, USA) was used for the statistical analyses.
 Results 
 Participants 
 Of the 183 participants randomised to either continue 
therapeutic CPAP ( n = 81) or withdraw from CPAP ( n = 
102), 175 completed the trial and provided BP data 
( Fig. 1 ). Two patients in the therapeutic CPAP and 4 pa-
tients in the withdrawal group discontinued the inter-
vention. One participant in each group did not measure 
BP on a daily basis. Recruitment for the first trial  [20] 
started in August 2009 and the last patient’s visit  [32] 
took place in August 2015. The baseline characteristics of 
the 2 treatment groups were comparable and are shown 
in  Table 1 .
Randomised (n = 183)
Allocated to therapeutic CPAP (n = 81)
Discontinued intervention (n = 2)
No blood pressure data availabe (n = 1)
Analysed (n = 78)
 Assessed for eligibility (n =1,805)
Discontinued intervention (n = 4)
No blood pressure data availabe (n = 1)
Analysed (n = 97)
Allocated to CPAP withdrawal (n = 102)
Excluded  (n = 1,622)
– Not meeting inclusion critera (n = 133)
– Declined to participate (n = 625)
– Met exlusion criteria (n = 864)
 Fig. 1. Patient selection flow chart. 
 Table 1. Baseline patient characteristics
Therapeutic 
CPAP 
(n = 78)
CPAP 
withdrawal 
(n = 97)
Age, years 63.4 ± 7.9 63.5 ± 8.9
Male sex, n (%) 64 (82) 81 (83.5)
BMI 33.6 ± 5.8 33.5 ± 5.9
Neck circumference, cm 44.1 ± 4.1 44.0 ± 4.1
Never smoker, n (%) 38 (48.7) 39 (40.2)
Current smoker, n (%) 9 (11.5) 12 (12.4)
Former smoker, n (%) 31 (39.7) 46 (47.4)
Hypertension, n (%) 50 (64.1) 74 (76.3)
Mean number of 
antihypertensive drugs 1.4 ± 1.4 1.6 ± 1.4
Calcium antagonist, n (%) 19 (24.4) 30 (30.9)
Beta-blocker, n (%) 19 (24.4) 24 (24.7)
ACE inhibitor or ARB, n (%) 40 (51.3) 60 (61.9)
Diabetes, n (%) 19 (24.4) 24 (24.7)
Dyslipidaemia, n (%) 31 (39.7) 36 (37.1)
Original AHI, events/h 44.0 ± 21.5 43.6 ± 20.1
Original ODI, events/h 37.3 ± 18.6 37.6 ± 18.0
Original ESS score 13.8 ± 3.3 13.9 ± 3.7
 Data are presented as means ± standard deviation unless 
otherwise mentioned. CPAP, continuous positive airway pressure; 
BMI, body mass index; ACE, angiotensin-converting enzyme; 
ARB, angiotensin receptor blocker; AHI, apnoea-hypopnoea 
index; ODI, oxygen desaturation index; ESS, Epworth Sleepiness 
Scale.
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 Table 2. Treatment effects on within-visit office blood pressure and heart rate variability
Therapeutic CPAP (n = 78) CPAP withdrawal (n = 97)  Treatment effect1
baseline follow-up baseline follow-up dif ference in 
change be -
tween groups
95% CI p value
SD office SBP, mm Hg 4.55 (2.90) 4.37 (2.19) 4.88 (2.59) 5.52 (3.69) +1.14 +0.20, +2.09 0.02
SD office DBP, mm Hg 3.26 (2.26) 3.48 (2.44) 3.04 (1.93) 3.82 (2.91) +0.36 –0.45, +1.18 0.38
SD office HR, bpm 2.38 (2.05) 1.98 (1.79) 1.86 (1.36) 2.58 (2.72) +0.67 –0.05, +1.39 0.07
Data are presented as means (SD) unless otherwise mentioned. CPAP, continuous positive airway pressure; SD, standard deviation; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate. 1 Treatment effect adjusted for baseline differences.
 Table 3. Longitudinal short- and intermediate-term home blood pressure and heart rate variability (days 1 – 13)
Therapeutic 
CPAP (n = 78)
CPAP with
drawal (n = 97)
Difference 
between groups
95% CI p value
Short-term morning home BP and HR variability (days 1 – 13)1
SD SBP, mm Hg 4.97 (1.57) 5.03 (1.42) +0.06 –0.39, +0.50 0.81
SD DBP, mm Hg 3.37 (1.09) 3.50 (1.20) +0.13 –0.21, +0.48 0.46
SD HR, bpm 2.19 (1.01) 2.32 (1.19) +0.13 –0.20, +0.47 0.43
Intermediate-term day-to-day home BP and HR variability (days 1 – 13)2
SD SBP, mm Hg 6.88 (2.45) 7.06 (2.33) +0.19 –0.53, +0.90 0.61
SD DBP, mm Hg 4.73 (1.70) 4.59 (1.53) –0.14 –0.62, +0.35 0.58
SD HR, bpm 4.73 (2.58) 4.99 (2.35) +0.26 –0.48, +0.99 0.49
Data are presented as means (SD) unless otherwise mentioned. CPAP, continuous positive airway pressure; BP, blood pressure; HR, heart 
rate; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure. 1 Mean daily SD of 3 repeated home BP measurements 
over 2 weeks: (SDtriplet1 + SDtriplet2 + … + SDtriplet13)/13. 2 SD of daily mean home BP over 2 weeks: SD of (BP1 + BP2 + … + BP13).
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 Fig. 2. Individual plots showing changes in within-visit blood pressure variability from baseline to follow-up in the group continuing 
therapeutic CPAP (left) and in the group withdrawn from CPAP therapy (right). CPAP, continuous positive airway pressure; SD, stan-
dard deviation. 
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 Treatment Effect on Within-Visit Variability in
BP and HR 
 CPAP withdrawal was associated with a statistically 
significant increase in within-visit variability in office sys-
tolic BP (between-group change in SD, +1.14 mm Hg, 
95% CI +0.20/+2.09,  p = 0.02), whereas it had no effect on 
variability in office diastolic BP (+0.36 mm Hg, 95% CI 
–0.45/+1.18,  p = 0.38) compared with continuing thera-
peutic CPAP ( Table 2 ;  Fig. 2 ). There was a trend towards 
higher within-visit HR variability in the CPAP therapy 
withdrawal group compared to the group continuing 
therapeutic CPAP (between-group change in SD, +0.67 
bpm, 95% CI –0.05/+1.39,  p = 0.07) ( Table 2 ).
 Longitudinal Variability in Morning Home
BP and HR 
 Short-term variability in neither systolic home BP (dif-
ference between groups in SD, 0.06 mm Hg, 95% CI 
–0.39/+0.50,  p = 0.81) nor diastolic home BP (difference 
between groups in SD, +0.13 mm Hg, 95% CI –0.21/+0.48, 
 p = 0.46) or HR (difference between groups in SD, +0.13 
bpm, 95% CI –0.20/+0.47,  p = 0.43) differed significantly 
between the 2 treatment groups over the study period 
( Table 3 ;  Fig. 3 ).
 Longitudinal Day-to-Day Variability in Home
BP and HR 
 Day-to-day variability in systolic BP (difference be-
tween groups in SD, +0.19 mm Hg, 95% CI –0.53/+0.90, 
 p = 0.61), diastolic BP (difference between groups in SD, 
–0.14 mm Hg, 95% CI –0.62/+0.35,  p = 0.58), and HR 
(difference between groups in SD, +0.26 bpm, 95% CI 
–0.48/+0.99,  p = 0.49) did not differ significantly between 
therapeutic CPAP and CPAP withdrawal over the study 
period of 2 weeks ( Table 3 ).
 Treatment Effect on OSA Severity and Daytime 
Sleepiness 
 CPAP withdrawal was associated with a return of 
OSA (between-group change in apnoea-hypopnoea in-
dex, +29.4, 95% CI +25.1/+33.7,  p < 0.001) accompanied 
by an increase in daytime sleepiness (between-group 
change in Epworth Sleepiness Scale score, +2.1, 95% CI 
+1.2/+2.9,  p < 0.001) compared to therapeutic CPAP 
( Table 4 ).
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 Fig. 3. Short-term variability in morning home systolic blood pres-
sure after randomisation over the study period compared between 
the 2 groups. Each point represents the SD of a triplicate measure-
ment of systolic home blood pressure (group mean) over 13 days 
after randomisation. CPAP, continuous positive airway pressure; 
SD, standard deviation. 
 Table 4. Treatment effects on OSA severity and daytime sleepiness
Therapeutic CPAP (n = 78) CPAP withdrawal (n = 84) Treatment effect
baseline follow-up baseline follow-up difference in 
change be-
tween groups
95% CI p value
AHI 2.4 (2.3) 3.2 (3.8) 2.8 (3.4) 33.1 (19.3) +29.4 25.1, 33.7 <0.001
ODI 2.9 (4.0) 2.9 (3.6) 3.3 (3.9) 34.4 (19.3) +31.1 26.9, 35.4 <0.001
ESS 7.2 (3.5) 7.0 (4.0) 7.6 (3.6) 9.5 (4.4) +2.1 1.2, 2.9 <0.001
Data are presented as means (standard deviation) unless otherwise mentioned. OSA, obstructive sleep apnoea; CPAP, continuous 
positive airway pressure; AHI, apnoea-hypopnoea index (in events/h); ODI, oxygen desaturation index (in events/h); ESS, Epworth 
Sleepiness Scale (in points; max. 24 points).
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 Discussion 
 This analysis of the effect of CPAP therapy withdraw-
al on daytime BPV found a slight increase in within-visit 
variability in systolic office BP in patients with moderate-
to-severe OSA. Although our data from several ran-
domised controlled trials have demonstrated this modest 
effect of recurrence of OSA on short-term variability in 
 office BP, it has not found an effect of OSA on short-term 
variability (morning BPV over 2 weeks) or intermediate-
term variability (day-to-day variability over 2 weeks) in 
 home BP. Furthermore, the treatment effect on systolic 
within-visit BPV seems rather modest and presumably is 
unlikely to be relevant  [33] .
 Using the same trial design, previous CPAP withdraw-
al studies have found an increase in BP  [20, 31, 34] and 
sympathetic activity  [20] and reductions in endothelial 
function  [20, 27, 30] accompanying the return of OSA, 
indicating a possible pathophysiological explanation for 
higher BPV. Thus, the marginally accentuated within-
visit variability in office systolic BP might mostly be ex-
plained by a higher susceptibility to the “white coat” effect 
 [35] as a consequence of an increased sympathetic tone in 
untreated OSA.
 To our knowledge, this is the largest data collection on 
treatment effects of CPAP therapy on daytime BPV in 
patients with OSA. Whether the findings regarding short-
term therapy withdrawal are comparable to effects of 
long-term CPAP therapy withdrawal remains uncertain. 
However, as previously shown  [20] , even short-term 
CPAP withdrawal usually leads to a rapid recurrence of 
OSA and is associated with distinct pathophysiological 
consequences such as impaired endothelial function, in-
creased urinary catecholamine excretion, and elevation of 
both BP and HR. Treatment effects of CPAP therapy are 
often underestimated due to poor patient compliance. 
Therefore, in our trials, only previously optimally CPAP-
adherent patients were randomised to either continue or 
withdraw from CPAP therapy, and a per-protocol analy-
sis was employed, so that a maximal treatment effect 
could be expected. Thus, the applied study model can be 
deemed suitable to evaluate physiological and therapeutic 
effects on BPV.
 Despite convincing pathophysiological concepts link-
ing the effects of OSA and their possible influence on BPV 
 [16, 23, 24, 36] , previous trials evaluating the effects of 
CPAP therapy on BPV have come to contradictory con-
clusions. Altered BPV has been found in previously un-
treated and otherwise healthy OSA patients  [24] . In a re-
cent uncontrolled prospective study, Pengo et al.  [29] in-
vestigated changes in within-visit variability in office BP 
in 78 newly diagnosed patients suffering from severe OSA. 
The analysis was stratified according to whether patients 
were hypertensive or not. Hypertensive subjects were not 
treated with antihypertensive medication either prior to 
or during the intervention period. Patient data were re-
corded at baseline and again 2 weeks after initiating CPAP 
therapy. At follow-up, a reduction of within-visit variabil-
ity in office systolic BP and HR could be detected, and, 
while observed in both groups, this reduction was more 
pronounced in the hypertensive patients, most likely re-
flecting the effect of CPAP therapy on sympathetic activa-
tion. Although in our study the majority of the subjects 
were diagnosed with hypertension, BP in all participants 
was well controlled, thus possibly masking a larger effect 
of CPAP withdrawal on systolic BP variability.
 In contrast, a randomised placebo-controlled trial of 
only 41 OSA patients with a respiratory disturbance index 
>15/h could not find a beneficial effect from 1 week of 
CPAP therapy on BPV  [28] . Although a higher respiratory 
disturbance index and elevated urine norepinephrine were 
positively related to BPV, there was no significant effect 
due to therapeutic CPAP versus placebo, since BPV de-
clined equally in both study arms. However, all of these 
studies were based on a rather small study population. Tak-
ing into account the existing evidence from the aforemen-
tioned trials  [24, 28, 29] , and adding the results of our anal-
ysis of randomised controlled trials, the data suggest that 
CPAP has at most only a minor effect on daytime BPV.
 Although we used standardised BP measurement 
methods to compile the data presented in our study, there 
are some possible limiting factors. First, the treatment in-
tervention lasted for only 2 weeks. Secondly, analysis of 
BPV including home measurements of BP relies on pa-
tient compliance. Even though the patients were instruct-
ed as to when and how to correctly use the measurement 
device, there was only limited possibility of ensuring the 
proper conduct of those measurements. While 24-h am-
bulatory and beat-to-beat BPV provide different patho-
physiological information on daytime BPV  [37] , stan-
dardised visit-to-visit office BPV and day-to-day home 
BPV have been shown to predict outcome in other patient 
groups and are an accepted method of assessing BPV  [11, 
38, 39] . Perhaps most importantly, antihypertensive 
medication is known to have an effect on BPV which de-
pends on the type of medication. Calcium channel block-
ers and beta-blockers are commonly used to treat hyper-
tension. However, they seem to have opposite effects on 
BPV, independently of their general effects on mean BP. 
In contrast to beta-blockers, calcium channel blockers 
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have been shown to effectively and consistently reduce 
BPV  [40] . As the patients in this study were asked to con-
tinue their medication regimen over the course of the in-
tervention, it is conceivable that despite recurrence of 
OSA, more distinct changes in BPV may have been 
masked by medication. In this cohort, all hypertensive 
subjects were treated, and BP at baseline in these patients 
was well controlled. On the other hand, whereas in the 
current study medication was not withheld, in the trial by 
Bao et al.  [28] patients had been taken off antihyperten-
sive medication for 3 weeks prior to the beginning of the 
study, and still there was no effect of CPAP on BPV.
 The results of this study, coming from 4 well-designed 
randomised controlled trials, provide data regarding 
CPAP therapy effects on daytime BPV. Despite the lack 
of evidence of CPAP therapy withdrawal importantly af-
fecting daytime BPV, repetitive  nocturnal BP surges up to 
80 mm Hg seen with OSA due to apnoea- and hypop-
noea-associated arousals  [41] are abolished by CPAP 
therapy. Therefore, a long-term beneficial effect on the 
cardiovascular system from CPAP with regard to BPV 
may still be possible. Steinhorst et al.  [23] recently showed 
that hypertension is primarily associated with increased 
night-time BPV rather than daytime BPV. OSA affects 
cardiovascular regulatory mechanisms most dramatically 
during sleep, which potentially explains the lack of a 
strong association between OSA and daytime BPV. The 
pathophysiology of OSA in hypertension is linked to 
blunting of the physiological nocturnal dipping pattern 
of BP and arousal-associated repetitive BP surges, thus 
possibly having an impact on the development of resis-
tant hypertension in OSA patients  [42] . However, the 
characteristics of BP changes in OSA also include an im-
paired baroreflex and sustained daytime hypertension, 
especially in the morning  [43, 44] . Consecutively, we ex-
pected morning BPV to be affected by the nocturnal con-
sequences of OSA, an assumption that could not entirely 
be verified. However, since OSA is common, is often co-
existent with a cluster of traditional cardiovascular risk 
factors, and can be effectively treated, an investigation of 
the preventive effects of CPAP remains a topic for future 
long-term trials.
 In summary, while within-visit variability in systolic 
BP slightly increased in response to CPAP therapy with-
drawal, the clinical relevance of this change is disputable 
despite a possible blunting effect of antihypertensive 
drugs on BPV. In conclusion, it is unlikely that OSA con-
tributes to cardiovascular risk via elevated daytime BPV.
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